CBS New York Features Medical Marijuana, Inc. Investment Axim …

SAN DIEGO, Feb. 6, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment AXIM® Biotechnologies, Inc. (OTC: AXIM) was featured on a CBS New York News segment about the Company’s clinical trials for its CanChew Plus® cannabidiol (CBD) chewing gum for the treatment of patients with irritable bowel syndrome (IBS), a disease that affects up to 15% of the world population.

The segment includes an in-depth interview with CEO of AXIM® Biotechnologies Dr. George E. Anastassov, MD, DDS, MBA about the functionality of CanChew Plus® and AXIM® CTO Lekhram Changoer about how the double-blind, placebo-controlled trial is being conducted at Wageningen University in the Netherlands. In addition, the report interviews a CanChew® customer who gives testimony to the product’s positive effects for gout and IBS.

„It’s motivating

... read more at: http://www.military-technologies.net/2017/02/06/cbs-new-york-features-medical-marijuana-inc-investment-axim-biotechs-flagship-cbd-chewing-gum-ibs-clinical-trial/

by